Research programme: autologous T cell cancer therapeutics - Kite Pharma/National Cancer Institute

Drug Profile

Research programme: autologous T cell cancer therapeutics - Kite Pharma/National Cancer Institute

Alternative Names: anti-KRAS-mutation; anti-SSX2 TCR; KITE-439; KRAS TCR; NEO Antigens; SSX2 TCR

Latest Information Update: 04 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kite Pharma; National Cancer Institute (USA)
  • Class Cell therapies; Gene therapies
  • Mechanism of Action Antigen receptor antagonists; Cell replacements; Gene transference; T-cell receptor antigen antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer; Multiple myeloma

Most Recent Events

  • 03 Oct 2017 Kite Pharma has been acquired by Gilead Sciences
  • 08 Aug 2017 KITE plans a phase I trial of KITE 585 for Multiple myeloma (Second-line therapy or greater) in second half of 2017 (IV) (NCT03318861)
  • 08 Aug 2017 Kite Pharma files an IND application with the FDA in USA for Multiple myeloma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top